Real-world study of aflibercept for age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have been diagnosed with wet age-related macular degeneration (nAMD)
- Your eye pressure in the study eye is 25 mmHg or lower
- Your other eye has not received anti-VEGF injections (except aflibercept) within the last 28 days
- You have no eye infections or severe inflammation in the study eye
- You are not allergic to aflibercept
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new investigational injection, QL1207H, against an already approved drug (aflibercept) for people with wet age-related macular degeneration, a condition that causes rapid central vision loss. The goal is to see if the new injection works as well or better at stopping further vision loss and possibly improving sight.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a new dose of aflibercept given on different schedules for people with PCV, a type of vision loss. It aims to see which schedule works best and how long the benefit lasts.
This trial tests a higher dose of aflibercept given on a flexible schedule for people who have not yet been treated for wet age-related macular degeneration (nAMD). It aims to see if this approach is safe and effective at improving vision.
This study tests a new investigational drug called BETA-TT8 for people with wet age-related macular degeneration (wet AMD) who have already been treated with standard therapy (aflibercept). The goal is to see if this new treatment is safe and effective in improving vision.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.